Crossmark

P-selectin glycoprotein ligand-1 (PSGL-1/CD162) is incorporated into clinical HIV-1 isolates and can mediate virus capture and subsequent transfer to permissive cells

Crossref DOI link: https://doi.org/10.1186/s12977-022-00593-5

Published Online: 2022-05-21

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Burnie, Jonathan

Persaud, Arvin Tejnarine

Thaya, Laxshaginee

Liu, Qingbo

Miao, Huiyi

Grabinsky, Stephen

Norouzi, Vanessa

Lusso, Paolo

Tang, Vera A.

Guzzo, Christina https://orcid.org/0000-0002-3042-0976
Funding

Funding for this research was provided by:

Institute of Infection and Immunity (PJH 175379)

Natural Sciences and Engineering Research Council of Canada (RGPIN-2019-06442, CGSM)

Ministry of Ontario (Ontario Graduate Scholarship)
License Information

Text and Data Mining valid from 2022-05-21

Version of Record valid from 2022-05-21
More Information

Article History

Received: 2 December 2021

Accepted: 21 April 2022

First Online: 21 May 2022

Declarations

:

: Whole blood from healthy donors was acquired in accordance with University of Toronto’s Research Ethics Board approval (protocol #00037384), with all donors providing written informed consent. Viremic plasma samples were collected in accordance with a protocol approved by the Institutional Review Board of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (ClinicalTrials.gov number NCT00039689). All study subjects provided written informed consent.

: Not applicable.

: Authors declare no potential competing interests.

Document is current

Any future updates will be listed below